• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Scotiabank initiated coverage on NewAmsterdam Pharma with a new price target

    3/14/24 7:41:08 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email
    Scotiabank initiated coverage of NewAmsterdam Pharma with a rating of Sector Outperform and set a new price target of $35.00
    Get the next $NAMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    3/14/2024$35.00Sector Outperform
    Scotiabank
    1/18/2024$30.00Buy
    Guggenheim
    1/16/2024$37.00Overweight
    Piper Sandler
    More analyst ratings

    $NAMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on NewAmsterdam Pharma with a new price target

      Citigroup initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $42.00

      6/17/25 7:50:10 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on NewAmsterdam Pharma with a new price target

      Stifel initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $44.00

      6/10/25 8:09:06 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma with a new price target

      Cantor Fitzgerald initiated coverage of NewAmsterdam Pharma with a rating of Overweight and set a new price target of $42.00

      6/4/25 7:45:30 AM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care